Nader Sanai
Clinical trials sponsored by Nader Sanai, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to reach brain tumors in recurrent glioblastoma Results expected Sep 2026 (estimated)
- New smart drug takes aim at Hard-to-Treat brain cancers Results expected Jul 2027 (estimated)
- Can a new pill reach brain tumors and halt their growth? Results expected Jul 2027 (estimated)
-
New drug-radiation combo targets deadly brain tumors in early trial
Disease control OngoingThis early-phase trial tests whether adding the drug quisinostat to standard radiation therapy can help control grade 4 glioblastoma, a fast-growing brain cancer. It includes up to 30 adults with either newly-diagnosed or recurrent tumors. Researchers first measure how much drug …
Early phase 1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug-radiation combo targets deadly brain cancer
Disease control OngoingThis early-phase trial tests whether adding the drug AZD1390 to standard radiation therapy can help people with a fast-growing brain tumor called glioblastoma (grade 4 glioma). The study includes both newly diagnosed and recurrent patients. First, researchers measure how much dru…
Early phase 1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a pill reach and fight aggressive brain tumors? early trial hints at possibility
Disease control OngoingThis early-phase trial tests the drug niraparib (Zejula) in people with two types of brain cancer: newly diagnosed glioblastoma and recurrent glioma with specific genetic changes (IDH mutation and ATRX loss). The study first checks if the drug reaches the tumor tissue, then gives…
Early phase 1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can a pill reach brain tumors? new trial tests ribociclib before surgery
Disease control OngoingThis trial tests whether the drug ribociclib can reach brain tumors in people with recurrent high-grade glioma or meningioma. About 48 participants take the drug before their scheduled tumor-removal surgery. The goal is to measure how much drug gets into the tumor and surrounding…
Early phase 1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC